Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cachexia | 11 | 2026 | 74 | 3.010 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2026 | 69 | 0.910 |
Why?
|
| Head and Neck Neoplasms | 6 | 2025 | 561 | 0.790 |
Why?
|
| Ovarian Neoplasms | 2 | 2026 | 595 | 0.700 |
Why?
|
| Muscular Atrophy | 5 | 2025 | 87 | 0.580 |
Why?
|
| Muscle, Skeletal | 8 | 2025 | 1789 | 0.500 |
Why?
|
| Single-Chain Antibodies | 1 | 2014 | 13 | 0.430 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2014 | 80 | 0.420 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 153 | 0.390 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 2214 | 0.390 |
Why?
|
| Lymph Nodes | 1 | 2014 | 503 | 0.350 |
Why?
|
| Neoplasms | 2 | 2024 | 2906 | 0.340 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 870 | 0.290 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 2382 | 0.270 |
Why?
|
| Colorectal Neoplasms | 3 | 2020 | 866 | 0.270 |
Why?
|
| Musculoskeletal Development | 1 | 2025 | 5 | 0.230 |
Why?
|
| Facial Paralysis | 2 | 2022 | 23 | 0.230 |
Why?
|
| Liver Neoplasms | 3 | 2020 | 776 | 0.220 |
Why?
|
| Vincristine | 1 | 2025 | 142 | 0.220 |
Why?
|
| Free Tissue Flaps | 2 | 2024 | 54 | 0.220 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2025 | 178 | 0.210 |
Why?
|
| Masseter Muscle | 1 | 2024 | 3 | 0.210 |
Why?
|
| Gracilis Muscle | 1 | 2022 | 2 | 0.190 |
Why?
|
| Sarcopenia | 2 | 2024 | 91 | 0.180 |
Why?
|
| Temporal Bone | 1 | 2020 | 48 | 0.160 |
Why?
|
| Wasting Syndrome | 1 | 2020 | 12 | 0.160 |
Why?
|
| Bone Neoplasms | 2 | 2020 | 259 | 0.150 |
Why?
|
| Postoperative Complications | 3 | 2022 | 2970 | 0.150 |
Why?
|
| Prevalence | 1 | 2026 | 2865 | 0.140 |
Why?
|
| Sex Factors | 1 | 2024 | 2105 | 0.140 |
Why?
|
| Female | 12 | 2026 | 78845 | 0.130 |
Why?
|
| Frailty | 1 | 2020 | 205 | 0.130 |
Why?
|
| Retrospective Studies | 6 | 2026 | 17291 | 0.130 |
Why?
|
| Age Factors | 1 | 2024 | 3342 | 0.130 |
Why?
|
| Disease Models, Animal | 6 | 2025 | 4560 | 0.130 |
Why?
|
| Risk Factors | 3 | 2026 | 10885 | 0.110 |
Why?
|
| Bone and Bones | 1 | 2018 | 317 | 0.110 |
Why?
|
| Animals | 9 | 2025 | 38030 | 0.110 |
Why?
|
| Male | 12 | 2025 | 72843 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 200 | 0.100 |
Why?
|
| Peptide Library | 1 | 2014 | 91 | 0.100 |
Why?
|
| Clone Cells | 1 | 2014 | 263 | 0.100 |
Why?
|
| Humans | 14 | 2026 | 145475 | 0.100 |
Why?
|
| Patient Discharge | 1 | 2020 | 992 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 925 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 978 | 0.100 |
Why?
|
| Mice | 8 | 2025 | 18329 | 0.090 |
Why?
|
| Aged | 4 | 2026 | 26153 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 848 | 0.090 |
Why?
|
| X-Ray Microtomography | 2 | 2025 | 108 | 0.090 |
Why?
|
| Middle Aged | 5 | 2026 | 36215 | 0.090 |
Why?
|
| Cell Line, Tumor | 4 | 2025 | 3542 | 0.080 |
Why?
|
| Prognosis | 3 | 2024 | 4316 | 0.080 |
Why?
|
| Organoselenium Compounds | 1 | 2009 | 10 | 0.080 |
Why?
|
| Selenium | 1 | 2009 | 50 | 0.070 |
Why?
|
| Adult | 4 | 2026 | 40777 | 0.070 |
Why?
|
| Osteoblasts | 1 | 2009 | 145 | 0.070 |
Why?
|
| Mitochondria, Muscle | 2 | 2020 | 120 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 2664 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2014 | 4148 | 0.060 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2025 | 15 | 0.060 |
Why?
|
| Tripartite Motif Proteins | 1 | 2025 | 39 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2025 | 5983 | 0.050 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2025 | 212 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2025 | 192 | 0.050 |
Why?
|
| Muscle Proteins | 1 | 2025 | 242 | 0.050 |
Why?
|
| Energy Metabolism | 2 | 2020 | 935 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2024 | 506 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 617 | 0.040 |
Why?
|
| Interleukin-6 | 2 | 2020 | 776 | 0.040 |
Why?
|
| Earache | 1 | 2020 | 6 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2020 | 76 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2020 | 142 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 2121 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2020 | 206 | 0.030 |
Why?
|
| Heterografts | 1 | 2018 | 143 | 0.030 |
Why?
|
| Organ Size | 1 | 2018 | 461 | 0.030 |
Why?
|
| Hearing Loss | 1 | 2020 | 249 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 1471 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 2134 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2018 | 332 | 0.030 |
Why?
|
| Health Status | 1 | 2020 | 832 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 1067 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1476 | 0.030 |
Why?
|
| Bone Density | 1 | 2018 | 487 | 0.030 |
Why?
|
| Body Composition | 1 | 2018 | 693 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 2823 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2020 | 3623 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2020 | 2445 | 0.020 |
Why?
|
| Cytokines | 1 | 2020 | 2067 | 0.020 |
Why?
|
| Mitochondria | 1 | 2018 | 992 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2009 | 112 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2009 | 112 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2009 | 162 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2009 | 166 | 0.020 |
Why?
|
| Cell Communication | 1 | 2009 | 328 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2022 | 11772 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 4295 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 666 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 5216 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2009 | 2046 | 0.010 |
Why?
|
| Inflammation | 1 | 2009 | 2878 | 0.010 |
Why?
|